Terbutaline is a prohibited drug except for athletes with a 2 therapeutic use exemption certificate; terbutaline's effects on 3 endurance performance are relatively unknown. 4 Purpose: To investigate the effects of two therapeutic (2mg; 4mg) 5 inhaled doses of terbutaline on 3km running time-trial 6 performance. 7 Methods: Eight males (24.3±2.4yrs; 77.6±8kg; 179.5±4.3cm) 8 and eight females (22.4±3yrs; 58.6±6kg; 163±9.2cm) free from 9 respiratory disease and illness provided written informed 10 consent. Participants completed 3 km running time-trials on a 11 non-motorised treadmill on three separate occasions following 12 placebo, 2 mg or 4 mg inhaled terbutaline, in a single-blind, 13 repeated-measures design. Urine samples (15mins post-exercise) 14 were analysed for terbutaline concentration. Data were analysed 15 using one-way repeated measures ANOVA, significance was set 16 at p<0.05 for all analyses.
Introduction 37
Short-acting β2-agonists are used therapeutically by athletes with 38 asthma related conditions to prevent and/or reverse the Doping Agency (WADA) regulations, who require alternative 48 β2-agonist therapy can apply for a therapeutic use exemption 49 certificate (TUE) in order to use inhaled terbutaline. 11
50
The prohibited status of terbutaline is due, in part, to the inability 51 to distinguish between therapeutic inhaled and therapeutic oral 52 doses (with all oral β2-agonists being banned under the WADA 53 code), given that an oral dose far exceeds the inhaled dose in 54 terms of the systemic bioavailability when given 55 therapeutically. 12, 13 In some athletes the need for the use of 56 terbutaline is justified, however there are currently no measures 57 in place to prevent an athlete with a legitimate TUE for 58 terbutaline from using the medication at a supratherapeutic dose 59 with impunity. 13 
60
The current WADA guidelines monitor the use of the inhaled 61 short-acting β2-agonists, salbutamol and formoterol via a urinary 62 threshold limit, above which will present an adverse analytical 63 finding (AAF). 11 For salbutamol this limit is 1000 ng·mL -1 with 64 a decision limit of 1200 ng·mL -1 and for formoterol this limit is 65 40 ng·mL -1 with a decision limit of 50 ng·mL -1 , with any levels 66 over this presenting an AAF. The current guidelines for use 67 indicate that no more than 1600 µg salbutamol can be inhaled in 68 a 24 hour period and within this no more than 800 µg can be 69 inhaled in a 12 hour period, with the equivalent for formoterol 70 being 54 µg over a 24 hour period. 11 If a threshold for terbutaline 71 could be determined, this would enable it to be monitored in 72 much the same way as both salbutamol and formoterol, 73 preventing an athlete with a TUE for terbutaline from potentially 74 using the medication at a supratherapeutic dose. Recently threshold was able to be established due to high variability 96 between individuals. It is therefore important to assess urinary 97 levels of terbutaline for doping control purposes.
98
Evidence exists that the use of terbutaline at a supratherapeutic 99 dose has the potential to be ergogenic. 17, 18 These purported 100 effects are due to the fact that short-acting β2-agonists (a class of 101 sympathomimetic amines) are able to activate the β2 adrenergic 102 receptors within the body, which are mainly present on bronchial 103 smooth muscle. [19] [20] [21] Activation of the β2 adrenergic receptors 104 reverses the constriction of bronchial smooth muscle during 105 bronchoconstriction. These same β2 receptors are also present on 106 cardiac smooth muscle and skeletal muscle. 21, 22 Adrenergic 107 activation of skeletal muscle has the potential to improve 108 musculoskeletal function and thus has the potential to be 109 ergogenic during exercise performance. 23 Recent investigations 110 suggest an acute supratherapeutic inhaled dose (15 mg) of 111 terbutaline may have ergogenic action in sprint cycling 112 performance. 8, 9, 14, 18 This 15 mg dose is approximately eight 113 times the recommended therapeutic dose for inhaled terbutaline 114 and in athletes with a TUE this would not be permitted according 115 to the WADA code, 11 however current regulations would not be 116 able to accurately detect this misuse of terbutaline, due to a lack 117 of urinary thresholds with which to monitor terbutaline use.
118
Given the ergogenic potential of supratherapeutic inhaled 119 terbutaline, it remains to be determined whether athletes using 120 terbutaline therapeutically to treat asthma symptoms could also 121 experience an ergogenic effect, traditionally the therapeutic dose 122 of inhaled terbutaline is between 1-2 mg, however studies have 123 shown therapeutic use as high as 4 mg. 10, 16 
124
The aim of the present study was to examine the potential x (0.02/(urine specific gravity -1)). Post time trial blood lactate was greater following 4 mg inhaled 264 terbutaline (10.7 ± 2.3 mmol·L -1 ) when compared to the placebo 265 trial (8.9 ± 1.8 mmol·L -1 ; P = 0.02; Figure 3 ). There were no 266 differences in gas exchange variables for VO2 (49.1 ± 7.7; 49.3 267 ± 5.2; 48.9 ± 5.1) VCO2 (50.3 ± 5.9; 52.5 ± 5.5; 52.1 ±4.5) or 268 RER (1.08 ± 0.1; 1.09 ± 0.05; 1.12 ± 0.07), for placebo, 2 mg 269 inhaled and 4 mg inhaled terbutaline, respectively. Figure 4) .
274
There was a significant difference in FEV1 between trial 275 conditions post-inhalation of 2 mg and 4 mg terbutaline (Table   276 2). There were no differences between FEV1 values in the 277 placebo trial following terbutaline administration or following 278 time-trial completion, there was no difference in baseline lung 279 function values between conditions. There was a significant difference in post inhalation FEV1 values compared to placebo 281 (P=0.007; P=0.003) for both 2 mg and 4 mg inhalation trials, 282 respectively (Table 2; Figure 5 ). Interestingly, the difference in 283 FEV1 post time-trial between conditions was not significant 284 (P=0.06) ( Figure 5) , possibly due to a slightly raised FEV1 285 following exercise in the placebo trial.
286
There was no significant difference (P=0.195) in urine 287 concentration between either the 2 mg inhalation or the 4 mg 288 inhalation post time-trial in males or females with mean ± SD 289 for the pooled groups (306 ± 288 ng·mL -1 ; 435 ± 410 ng·mL -1 ) 290 and the peak values (956 ng·mL -1 ; 1244 ng·mL -1 ) for 2 mg 291 inhaled terbutaline and 4 mg inhaled terbutaline, respectively 292 ( Figure 6 ). performance. 9, 14, 17, 18 With this in mind, the distribution of the 364 high therapeutic dose (4 mg) in the present study, would likely 365 have been lower than that of the 15 mg inhaled dose studies, 366 therefore there could have been a lower potency of the β2-agonist.
367
Given that the present study's evidence stems from 368 recreationally active individuals, it is likely that these results are 369 transferrable to highly trained individuals, (i.e. the physiological 370 response would be the same in both groups). Although this is a 371 limitation, ethically, it would not have been possible to perform 372 this study in an elite population, due to the athletes' 373 responsibility to undertake out-of-competition testing. competition, largely due to the inability to distinguish between 376 route of administration and total dose administered. 12, 16, 28 In the 377 present study we were able to measure urine concentrations of 2 378 mg and 4 mg doses of terbutaline, interestingly our values for 2 379 mg (305.5±288.3 ngˑml -1 ) inhaled terbutaline are lower than 
